10.

Estrogen dan Overactive kandung kemih

Analisa terakhir tentang penggunaan estrogen pada terapi saluran kemih bagian bawah telah dilakukan oleh Group Cocrane. Disimpulkan bahwa penggunaan estrogen akan dapat memberikan beberapa manfaat walaupun dapat menimbulkan efek pada jangka panjang. Dimana penggunaan estrogen dapat memperburuk inkontinensia.

11. Overactive kandung kemih yang sulit diatasi

Mayoritas pasien dapat merespon terhadap pemberian terapi konservatif dan obat-obatan, dimana yang lain tetap mengeluhkan masalah pada saluran kemih bagian bawah. Ada beberapa alternatif yang diberikan : a) Toxin Botulinum intravesical efek perbaikan bersifat sementara dan dapat memberikan resiko yang lebih parah pada kesulitan berkemih b) Neuromodulator - peripheral neuromodulator - sacral neuromodulator - cutaneous sacral neuromodulator

c) Tindakan operatif - sebagian kecil wanita yang masih gagal menggunakan terapi diatas, mengambil langkah tindakan operatif seperti bedah rekonstrusi, seperti diversi ileum, clam cytoplasty.

12. Kesimpulan
Overactive kandung kemih adalah kondisi umum dan keadaan yang sangat mengganggu yang memberikan efek yang sangat signifikan pada kualitas hidup. Tes fungsi ginjal dapat membantu dalam mendiagnosa wanita dengan simptoms yang tidak biasa. Mayoritas pasien dapat merespon baik terhadap pemberian terapi konservatif dan obat-obatan. Dimana yang lain (minoritas) dapat menggunakan toxin botulinum dan neuromodulator yang lebih efektif dibanding bedah rekonstruksi

DAFTAR PUSTAKA
[1] Haylen BT, de Ridder D, Freeman RM, et al. An International Urogynaecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J 2010;21:526. [2] Stewart WF, Corey R, Herzog AR, et al. Prevalence of overactive bladder in women: results from the NOBLE program. Int Urogynecol J 2001;12(3):S66. [3] Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff J, Wein AJ. How widespread are the symptoms of overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001;87(9):7606. [4] Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder and other lower urinary tract symptoms in five countries; results of the EPIC study. Eur Urol 2006;50:130615. [5] Anderson KE. The overactive bladder: pharmacologic basis of drug treatment. Urology 1997;50:7489. [6] Hashim H, Abrams P. Is the bladder a reliable witness for predicting detrusor overactivity? J Urol 2006;175:1915. [7] Jenkinson C, Coulter A, Wright L. Short Form 36 (SF-36) health survey questionnaire. Normative data for adults of working age. Br Med J 1993;306:143740. [8] Kelleher CJ, Cardozo LD, Khullar V, Salvatore S. A new questionnaire to assess the quality of life of urinary incontinent women. Br J Obstet Gynaecol 1997;104:13749. [9] Van Koeveringe GA. Effect of partial urethral obstruction on force development of the guinea pig bladder. Neurourol Urodyn 1993;12:5556. [10] Swithinbank L, Hashim H, Abrams P. The effect of fluid intake on urinary symptoms in women. J Urol 2005;174(July (1)):1879.

[11] Subak LL, Wing R, West DS, et al. PRIDE InvestigatorsWeight loss to treat urinary incontinence in overweight and obese women. N Engl J Med 2009;360(5):48190. [12] Jeffcoate TNA, Francis WJA. Urgency incontinence in the female. Am J Obstet Gynecol 1966;94:60418. [13] Jarvis GT, Millar DR. Controlled trial of bladder drill for overactive bladder. Br Med J 1980;281:13223. [14] Holmes DM, Stone AR, Barry PR, Richards CJ, Stephenson TP. Bladder training years on. Br J Urol 1983;55:6604. [15] Berghmans LC, Hendricks HJ, de Bie RA, van Waalwijk van Doorn ES, Bo K, van Kerrebroeck PE. Conservative treatment of urge urinary incontinence in women: a systematic review of randomised clinical trials. Br J Urol Int 2000;85:25463. [16] NICE Guideline 40. The Management of Urinary Incontinence in Women. Department of Health. www.nice.org.uk; 2006. [17] Hay-Smith J, Berghmans B, Burgio K, et al. Adult conservative management. In: Abrams P, Cardozo L, Khoury S, Wein A, editors. Incontinence. 4th edition Paris, France: Health Publication Ltd.; 2009. p. 1025120 [Editions 21]. [18] Andersson KE, Chapple CR, Cardozo L, et al. Pharmacological treatment of urinary incontinence. In: Abrams P, Cardozo L, Khoury S, Wein A, editors. Incontinence. 4th edition Paris, France: Health Publication Ltd.; 2009. p. 631700 [Editions 21]. [19] Hadorn DC, Baker D, Hodges JS, Hicks N. Rating the quality of evidence for clinical practice guidelines. J Clin Epidemiol 1996;49(7):74954. [20] Harbour R, Miller J. A new system for grading recommendations in evidence based guidelines. BMJ 2001;323:3346. [21] Chapple CR, Khullar V, Gabriel Z, Muston D, Bitoun CE, Weinstein D. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 2008;54(3):54362. [22] Diokno AC, Appell RA, Sand PK, et al. OPERA Stuy Group. Prospective, randomised, double blind study of the efficacy and tolerability of the extendedrelease formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc 2003;78(6):68795. [23] Chapple CR, Martinez-Garcia R, Selvaggi L, et al. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 2005;48:46470. [24] Herschorn S, Swift S, Guan Z, et al. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head to head placebo controlled trial. BJU Int 2009;105:5866. [25] Kaplan SA, Schneider T, Foote JE, Guan Z, Carlsson M, Gong J. Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head-to-head, placebo-controlled trial. BJU Int 2011;107(9):143240.

[25] Kaplan SA, Schneider T, Foote JE, Guan Z, Carlsson M, Gong J. Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head-to-head, placebo-controlled trial. BJU Int 2011;107(9):143240. [26] Alhasso AA, McKinlay J, Patrick K, Stewart L. Anticholinergic drugs versus non drug active therapies for overactive bladder syndrome in adults. Cochrane Database Syst Rev 2006;(4), doi:10.1002/14651858.CD003193.pub3. Art No: CD003193. [27] Cody JD, Richardson K, Moehrer B, Hextall A, Glazener CMA. Oestrogen therapy for urinary incontinence in post-menopausal women. Cochrane Database Syst Rev 2009;(4), doi:10.1002/14651858.CD001405.pub2. Art. No: CD001405. [28] Moehrer B, Hextall A, Jackson S. Oestrogens for urinary incontinence. Cochrane Database Syst Rev 2003;(2). [29] Tseng LH, Wang AC, Chang YL, Soong YK, Lloyd LK, Ko YJ. Randomized comparison of tolterodine with vaginal estrogen cream versus tolterodine alone for the treatment of postmenopausal women with overactive bladder syndrome. Neurourol Urodyn 2009;28(1):4751. [30] Serati M, Salvatore S, Uccella S, Cardozo L, Bolis P. Is there a synergistic effect of topical oestrogens when administered with antimuscarinics in the treatment of symptomatic detrusor overactivity? Eur Urol 2009;55(March (3)):713 9 [Epub 2008 June 20]. [31] Popat R, Apostolidis A, Kalsi V, Gonzales G, Fowler CJ, Dasgupta P. A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of Botulinum-A toxin. J Urol 2005;174:9849. [32] Dmochowski R, Chapple C, Nitti V, et al. Efficacy and safety of onabotulinum toxin A for idiopathic overactive bladder: a double-blind, placebo controlled randomised dose ranging trial. J Urol 2010;184:241622. [33] Sahai A, Dowson C, Kahn MS, Dasgupta P. Repeated injections of botulinum toxin-A for idiopathic detrusor overactivity. Urology 2010;75:5528. [34] Vandoninick V, van Balken MR, Finazzi Agro E, et al. Posterior tibial nerve stimulation in the treatment of urge incontinence. Neurourol Urodyn 2003;22:17 23. [35] Peters KM, Macdiarmid SA, Wooldridge LS, et al. Randomised trial of percutaneous tibial nerve stimulation versus extended release tolterodine: results from the overactive bladder innovative therapy trial. J Urol 2009;182:1055 61. [36] van Kerrebroeck PE, van Voskuilen AC, Heesakkers JP, et al. Results of sacral neuromodulation therapy for urinary voiding dysfunction: outcomes of a prospective, worldwide clinical study. J Urol 2007;178(November (5)):202934. [37] Monga A, Dmochowski R, Miller D. Evaluation of a novel, non invasive, patientmanaged neuromodulation system (PMNS) on urgency urinary incontinence and patient reported outcomes in subjects with overactive bladder syndrome who had previously failed therapy: a four week, multicentre, prospective randomised trial. Neurourol Urodyn 2011;30:9368. [38] Levin RM, Kitada S, Hayes L, et al. Experimental hyperreflexia: effect of intravesical administration of various agents. Pharmacology 1991;42:54. [39] Andersson KE. The overactive bladder: pharmacologic basis of drug treatment. Urology 1997;50:74. [40] Laval KU, Lutzeyer W. Spontaneous phasic activity of the detrusor: a cause of uninhibited contractions in unstable bladder. Urol Int 1980;35:1827. [41] Chapple C, Patroneva A, Raines S. Effect of an ATP-sensitive potassium channel opener in subjects with overactive bladder: a randomized double-blind placebo controlled study (ZD0947IL/0004). Eur Urol 2006:87986. [42] Chapple CR, Yamaguchi O, Ridder A. Clinical proof of concept study (Blossom) shows novel 3 adrenoceptor agonist YM178 is effective and well tolerated in the treatment of symptoms of overactive bladder. Eur Urol Suppl 2008;7: 239. [43] Green SA, Alon A, Ianus J, Mc Naughton, Tozzi CA, Reiss TF. Efficacy and safety of a neurokinin-1 receptor antagonist in postmenopausal women with overactive bladder with urge urinary incontinence. J Urol 2006;176:253540.